Related Experiment Video
Updated: Aug 23, 2026
Isolation of Mouse Megakaryocyte Progenitors
Published on: May 20, 2021
Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of
Kazunori Shibuya1, Tomoaki Kuwaki, Hiromichi Akahori
1Pharmaceutical Development Laboratories, Kirin Brewery Company Ltd., 3 Miyahara-cho, Takasaki, Gunma 370-1295, Japan.
Abstract:
We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.
